Title : A pharmacoeconomic analysis to compare cost-effectiveness of metformin plus teneligliptin with metformin plus glimepiride in patients of type-2 diabetes mellitus.

Pub. Date : 2019 Mar

PMID : 31041232






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Results: The cost-effectiveness for per unit reduction in HbA1c and FPG was significant in metformin plus glimepiride group as compared to the metformin plus teneligliptin group though it was comparable for both the groups for per unit PPG reduction. glimepiride hemoglobin subunit alpha 1 Homo sapiens
2 Conclusion: Compared to metformin plus teneligliptin, metformin plus glimepiride is a significantly cost-effective therapy when used as an initial combination therapy in patients of T2DM in lowering HbA1c and FPG. glimepiride hemoglobin subunit alpha 1 Homo sapiens